A Study to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinophilic Esophagitis
Brief description of study
Solrikitug is a humanized immunoglobulin (Ig) G1 monoclonal antibody that binds to human thymic stromal lymphopoietin TSLP is an up-stream regulator of the T-helper 2 immune response and has been shown to drive the Th2 inflammatory responses that are involved in allergic inflammatory disorders, including eosinophilic esophagitis (EoE). This is a Phase 2 study to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of solrikitug in patients with EoE.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
